天津医药

天津医药 ›› 2017, Vol. 45 ›› Issue (1): 100-103.doi: 10.11958/20161120

• 综述 • 上一篇    下一篇

疾病修饰药物在视神经脊髓炎谱系疾病中的应用进展

张超， 王春阳， 韩滨， 杨春生， 杨丽   

  1. 天津医科大学总医院
  • 收稿日期:2016-10-10 修回日期:2016-11-03 出版日期:2017-01-15 发布日期:2017-01-15
  • 通讯作者: 张超 E-mail:bjyb254@163.com
  • 基金资助:
    国家自然科学青年基金资助项目

Application progress of disease modifying drugs in neuromyelitis optica spectrum disorder

ZHANG Chao△, WANG Chun-yang, HAN Bin, YANG Chun-sheng, YANG Li #br# #br#   

  1. 1 Department of Neurology, Tianjin Medical University General Hospital, Tianjin 300052,China
  • Received:2016-10-10 Revised:2016-11-03 Published:2017-01-15 Online:2017-01-15
  • Supported by:
    National Natural Science Foundation of China

PDF (PC)

4132

摘要： 摘要： 视神经脊髓炎谱系疾病 （NMOSD）是以视神经和脊髓炎性脱髓鞘损害伴轴索变性坏死为特征的中枢神经 系统自身免疫性疾病， 具有高复发率和高致残性的特点。近年来， 随着对 NMOSD 发病机制的研究深入， 相关的免疫 治疗方法也得到迅速发展。这些免疫治疗策略统称为疾病修饰治疗， 用以改善疾病的进程和转归。本文就 NMOSD 的最新治疗进展做一综述， 以期指导临床中选择和应用疾病修饰药物 （DMD）。

关键词: 关键词：疾病修饰药物, 视神经脊髓炎谱系疾病, 水通道蛋白4, 单克隆抗体, 利妥昔单抗, 托珠单抗

Abstract: Abstract: Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disease of the central nervous system that is characterized by inflammatory demyelinating lesions and axonal degeneration in optic nerve and spinal cord. It has high relapse rate and high disability rate. In recent years, as the studies on mechanisms of NMOSD, related immune therapy strategies have been developed rapidly. These immunologic interventions are collectively called the disease modifying therapy, which are helpful in improving the course and outcome of the disease. In this review, the latest treatment progress in NMOSD is summarized to guide clinical choice and application of the medication.

Key words: Key words: disease modifying drugs, neuromyelitis optica spectrum disorder, AQP-4, monoclonal antibody, rituximab, tocilizumab